The Immunological and Blood Effects of STA-5326 Mesylate on Patients With Crohn's Disease
A Randomized, Double-blind, Pilot Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, to Investigate Peripheral Blood and Mucosal Mononuclear Cell Phenotype and Cytokine Responses in Patients With Crohn's Disease
This study will test whether a new experimental drug called STA-5326 mesylate will decrease inflammatory chemicals called cytokines in patients with Crohn's disease. The drug has prevented gut inflammation in mice and rats and has improved symptoms in humans with active Crohn's disease.
Patients with Crohn's Disease between 18 and 75 years of age and who have active disease symptoms may be eligible for this study. Candidates are screened with a review of their medical records, a medical history and physical examination, electrocardiogram, blood and urine tests, chest x-ray and tuberculin skin test. They fill out diary cards for 7 days (measuring their symptoms on the Crohn's Disease Activity Index, or CDAI) and complete a 32-item Inflammatory Bowel Disease Questionnaire (IBDQ) that surveys how their disease affects their live and activities.
Participants have a colonoscopy (an examination of the colon using a lighted tube) before starting the study medication. Colon tissue samples are biopsied during the procedure. Following the colonoscopy, patients are randomly assigned to receive either STA-5326 mesylate or placebo (sugar or dummy pill). They take four tablets a day and are seen in the clinic once a week (days 1, 8, 15, 22 and 29) for the following tests and procedures:
- Physical examination - Days 1, 8, 15, 22, 29
- Blood tests - Days 1, 8, 15, 22, 29
- Pharmacodynamic study (blood collected before the first dose of medicine and again after 1, 2, 4, 6 and 8 hours to measure levels of the drug in the blood) - Day 1
- CDAI and IBDQ - Days 1, 15, 29
- Review of medications and symptoms - Days 1, 8, 15, 22, 29
- EKG - Days 8, 29
- Pregnancy test for women of child-bearing potential - Days 15, 29
- Urine test - Day 29
After patients complete the above treatment and tests, they undergo a second colonoscopy within 48 hours of their last dose of study medication and may be offered another 1-week supply of medication. Those for whom additional treatment is deemed potentially beneficial are offered another 4-week course of drug or placebo (continuing whichever they took the first 4 weeks). They come to the clinic for two visits 2 weeks apart (days 43 and 57) for a physical examination, blood tests, EKG, pregnancy test for women, CDAI, IBDQ and review of medications and symptoms. A urine sample is collected only on day 57. A third colonoscopy is done after all the tests are completed on day 57, within 48 hours after the last dose of study medication.
Patients return to the clinic about 1 week after their final dose of study medication (day 36 for patients who complete only 1 month of treatment and day 64 for those who complete a second month of treatment) for a limited physical examination, blood tests, pregnancy test for women, CDAI and IBDQ, and a review of their medications and symptoms.
調査の概要
詳細な説明
The purpose of this study is to measure the mucosal immunological effects and peripheral blood effects of the oral IL-12/23 inhibitor, STA-5326 mesylate, in subjects with active Crohn's disease (CD). Crohn's disease is a chronic, relapsing inflammatory condition of the small and large bowel associated with excessive Th1 cytokine production. Since IL-12 is a key cytokine driving the Th1 response, novel therapies targeting IL-12 have been successful in treating CD in animal models and in humans. Data from humans and from animal models further suggest that both IL-12 and IL-23 may have a role in this active gut inflammation. STA-5326 mesylate is an oral drug that suppresses IL-12p40 production (a subunit shared by IL-12 and IL-23) in vitro and has apparent safety and clinical activity in a recent open-label trial of treatment for CD.
This protocol will enroll and randomize 12 subjects with moderate to severe active CD (CD Activity Index [CDAI] 220 to 450, inclusive) for 4 weeks of daily study drug treatment (9 subjects will receive 100 mg STA-5326 mesylate and 3 will receive placebo). Subjects will be evaluated for safety that will include monitoring of adverse events and concomitant medications, clinical laboratory testing, electrocardiogram (ECG) tracings, and physical examinations including vital signs. Efficacy assessments will include the CDAI, the Simple Endoscopic Score for CD (SES-CD), results from the Inflammatory Bowel Disease Questionnaire (IBDQ), and changes from Baseline for plasma C reactive protein (CRP) (measured by high sensitivity assay). In addition, immunologic effects (lymphocyte phenotyping cytokine secretion from peripheral blood and lamina propria mononuclear cells [LPMCs]) will be assessed. Descriptive statistics (n, mean, median, standard deviation, minimum and maximum range) will be used to summarize data for each treatment group.
研究の種類
入学
段階
- フェーズ2
連絡先と場所
研究場所
-
-
Maryland
-
Bethesda、Maryland、アメリカ、20892
- National Institute of Allergy and Infectious Diseases (NIAID)
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
- INCLUSION CRITERIA:
A subject is eligible for the study if all of the following criteria are met:
Has given written informed consent prior to Screening.
Is male or female aged 18 through 75 years.
Has CD diagnosed definitively prior to Screening (based upon clinical, endoscopic, radiologic imaging, or histological assessments).
Has a CDAI score of 220 to 450, inclusive.
If taking sulfasalazine or mesalamine, must have been using continuously for at least 2 months prior to randomization and at stable doses for at least 2 weeks prior to randomization.
If taking azathioprine, 6-mercaptopurine, or methotrexate, must have used continuously for at least 3 months prior to randomization and at stable doses for at least 1 month prior to randomization.
If taking oral antibiotics chronically, must have used continuously for at least 1 month prior to randomization and at stable doses for at least two weeks prior to randomization.
If taking corticosteroids, must be taking prednisone less than or equal to 20 mg daily (or equivalent), or budesonide less than or equal to 9 mg daily for at least 2 months prior to randomization and at stable doses for at least 2 weeks prior to randomization.
Not taking any potential CYP3A4 inhibitors/inducers (eg, macrolide antibiotics, HIV protease inhibitors, antifungals, grapefruit juice, St. John's Wort).
EXCLUSION CRITERIA:
A subject is excluded from the study if any of the following criteria are met:
General criteria:
Has any clinically significant disease (eg, renal, hepatic, neurological, cardiovascular, pulmonary, endocrinologic, psychiatric, hematologic, urologic, or other acute or chronic illness) that in the opinion of the investigator would make the subject an unsuitable candidate for this trial.
Is a woman who has a positive pregnancy test or who is breast-feeding
Is a woman of childbearing potential or a man who does not agree to use 2 forms of contraception during the course of the study and Follow-up period.
Has hypersensitivity to any of the components of STA 5326 mesylate drug product.
Has any of the following clinical chemistry values:
- AST greater than 2.0 x ULN.
- ALT greater than 2.0 x ULN.
- Serum bilirubin greater than 1.5 x ULN.
- Serum creatinine greater than 1.5 x ULN.
- Alkaline phosphatase greater than 2.5 x ULN.
Has a hemoglobin level less than 9 g/dL or hematocrit less than 30%.
Has a PT INR greater than 1.3 or PTT of 3 or more seconds longer than control values.
Has the following cell counts (cells/microliter):
- Platelets less than 100,000 or greater than 800,000.
- White blood count less than 3,500.
- Neutrophils less than 2000.
Has a history of any infection requiring intravenous antibiotics, a serious local infection (eg, cellulitis, abscess) or systemic infection (eg, pneumonia, septicemia) that occurred within 3 months of randomization.
Has a history of cancer within the past 5 years, with the exception of excised basal cell carcinoma, squamous cell carcinoma of the skin, or cervical carcinoma in situ.
Had a dependency for any illicit drug, chemical, or alcohol within the past 5 years.
Has a history of active tuberculosis, a positive PPD skin test, acute or chronic hepatitis B, hepatitis C, or human immunodeficiency virus (HIV).
Gastrointestinal criteria:
Has a current ileostomy or colostomy.
Has a proctocolectomy or total colectomy.
Has short bowel syndrome requiring enteral or parenteral nutrition supplementation or total parenteral nutrition.
Has a stool sample positive for gastrointestinal infection (eg, Clostridium difficile toxin, etc.) during Screening.
Has a history or diagnosis of ulcerative or indeterminate colitis.
Had bowel surgery in the previous 3 months.
Had severe intestinal tract stenosis or fixed strictures causing symptomatic obstruction within 6 months prior to randomization.
Prior medication criteria relative to randomization:
Received parenteral corticosteroids or corticotropin within 1 month prior to randomization.
Has had regular use of aspirin or other non-steroidal anti-inflammatory drugs within 2 weeks prior to randomization (other than use of chronic low dose aspirin [81 mg per day] for cardioprotective effects).
Received any investigational drug within 3 months prior to randomization.
Received cyclosporine, tacrolimus, sirolimus, or mycophenolate mofetil within 2 months prior to randomization.
Received any biological product (eg, infliximab, adalimumab, natalizumab, etc.) within 3 months prior to randomization.
Ever received treatment with STA-5326 mesylate, IL-12 antibodies, or other specific IL-12 inhibitors.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
協力者と研究者
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始
研究の完了
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
クローン病の臨床試験
-
Adelphi Values LLCBlueprint Medicines Corporation完了肥満細胞性白血病 (MCL) | 攻撃的な全身性肥満細胞症 (ASM) | SM w Assoc Clonal Hema Non-mast Cell Lineage Disease (SM-AHNMD) | くすぶり全身性肥満細胞症 (SSM) | 無痛性全身性肥満細胞症 (ISM) ISM サブグループが完全に募集されましたアメリカ
STA-5326の臨床試験
-
Synta Pharmaceuticals Corp.完了
-
National Institute of Allergy and Infectious Diseases...完了
-
Synta Pharmaceuticals Corp.National Institute of Allergy and Infectious Diseases (NIAID); National Institutes of Health...完了
-
Emory UniversitySynta Pharmaceuticals Corp.終了しましたステージ IVA 口腔扁平上皮がん | IVA期の喉頭扁平上皮がん | IVA期中咽頭扁平上皮がん | I期の下咽頭扁平上皮がん | I期喉頭扁平上皮がん | I期中咽頭扁平上皮がん | II期の下咽頭扁平上皮がん | II期喉頭扁平上皮がん | II期中咽頭扁平上皮がん | III期の下咽頭扁平上皮がん | III期の喉頭扁平上皮がん | III期の中咽頭扁平上皮がん | IVA期の下咽頭扁平上皮がん | III期口腔扁平上皮がん | I期口腔扁平上皮がん | II期口腔扁平上皮がんアメリカ
-
Synta Pharmaceuticals Corp.完了リンパ腫 | 白血病 | 血液悪性腫瘍 | Metastatic or Unresectable Solid Tumorsアメリカ
-
Genzyme, a Sanofi Company終了しましたクローン病イスラエル, アメリカ, ルーマニア, ウクライナ, 南アフリカ, カナダ, オーストラリア, ブルガリア, ロシア連邦, ニュージーランド, ブラジル